New insulin could cut need for daily injections
By Stephen Robinson, 27 September 2010
A new insulin in development may remove the need for daily injections and reduce glucose fluctuations, research suggests.
Data from a phase-2 trial showed treatment with new insulin degludec led to a more stable glucose-lowering effect in patients with type-1 diabetes than standard treatment.
An accompanying study showed that insulin degludec injected three times a week was as effective at lowering HbA1c levels as existing type-2 diabetes therapy.
The data were presented at the European Association for the Study of Diabetes (EASD) meeting in Stockholm last week.
In the first study, 54 patients with type-1 diabetes were given either insulin degludec or insulin glargine once daily and monitored for 12 days. Researchers studied treatment effects for 24 hours at days 6, 9 and 12.
Researchers found that the variability of treatment effects was lower among patients given insulin degludec than standard treatment.
Findings from another study also suggested the new insulin could be administered less often, which could improve adherence to treatment in insulin-naïve patients.
In a phase-2 trial, three-times-weekly insulin degludec was shown to be as effective as a once daily dose of standard treatment.
A trial of 184 type-2 patients compared insulin degludec once daily or three-times-weekly with insulin glargine.
It showed that the three treatments produced similar reductions in HbA1c and number of adverse effects.
Dr Iain Frame, director of research at Diabetes UK, described the study as ‘a small step forward’ in producing a new insulin formulation.
‘The next stage will be to test the formulations on larger numbers of people for a longer time period,’ he said.
- Related Drug Categories
- Related MIMS Tables
- Finger Prickers and Compatible Lancets
- Insulin Preparations
- Blood Glucose Testing Strips and Meters
- Related MIMS Guidelines and Summaries
- Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes (TA288)
- Exenatide Prolonged-Release Suspension for Injection in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes (TA248)
- Liraglutide for the Treatment of Type 2 Diabetes Mellitus (TA203)
Latest Articles from GP
Latest jobs Jobs web feed
- Salaried GP Millstream Medical Centre Competitive salary will be offered dependent on experience, Central Salisbury
- FULL TIME GP PARTNER Market Cross Surgery Lincolnshire Available on application., Rural South Lincolnshire - located bewteen Stamford and Grantham.
- Salaried GP - Essex Coben Medical Competitive salary offered, Essex North East of London
- Salaried GP Opportunity Oakridge Park Medical Centre To be discussed with applicant, The Practice is in Milton Keynes with excellent transport links to London and the North
- Out of Hours & Walk in Centre Midlands - Birmingham, Coventry, Hereford, Cardiff / Wales TOP RATES!! Medco Services Up to £95 per hour, Midlands - Various
- Locum GP - Essex and surrounding areas. Angel Human Resources LLP Excellent rates of pay and travel contributions paid to the Locum GP, Various choices of work offered to the Locum GP In Essex areas and surrounding areas